Figure 7: Effect of CpG treatment on human DCs.
From: High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9–TRIF pathway
(a) IDO protein expression was analysed in FL-DCs, either untreated or treated with 0.3 or 3 μg ml−1 CpG. (b) FL-DCs were assayed for IL-23 and TGF-β release after 0.3 or 3 μg ml−1 CpG exposure. Data are means±s.d. from four experiments. *P<0.05; Student’s t-test. (c) TLR9 associates with MYD88 and TRAF3 upon stimulation with 0.3 μg ml−1 CpG, but with TRIF and TRAF6 after stimulation with 3 μg ml−1 CpG. One experiment representative of several.
